LumicaX Co. develops, manufactures, and sells a wide range of solutions applicable in diverse markets. Their focus areas include clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. Notably, LumicaX’s technology leverages xMAP, which can simultaneously perform up to approximately 500 tests in a single run.

Vision and Mission: While specific vision and mission statements for LumicaX Co. are not publicly available, their commitment likely revolves around enhancing the quality of life through cutting-edge solutions. Their vision may involve revolutionizing healthcare and research, while their mission could be to provide innovative tools that address critical challenges in diagnostics and safety.

Noteworthy Points:

• LumicaX Co. has received seed funding, indicating investor confidence and growth potential.
• Their collaboration with Korea University Holdings underscores their commitment to research and development.
• LumicaX Co.’s technology combines artificial intelligence and advanced diagnostics, positioning them as a forward-thinking player in the industry.